These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433 [TBL] [Abstract][Full Text] [Related]
44. Prevention of restenosis after PTCA: role of calcium antagonists. Hoberg E; Kübler W J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S15-9. PubMed ID: 1725911 [TBL] [Abstract][Full Text] [Related]
45. Calcium-antagonists in preventing restenosis following coronary angioplasty. Hoberg E; Kübler W Cardiologia; 1991 Dec; 36(12 Suppl 1):225-7. PubMed ID: 1841774 [TBL] [Abstract][Full Text] [Related]
46. Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty. Schlant RC; King SB Circulation; 1989 Dec; 80(6 Suppl):IV88-92. PubMed ID: 2688988 [TBL] [Abstract][Full Text] [Related]
47. Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty. Preisack MB; Karsch KR Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331 [TBL] [Abstract][Full Text] [Related]
48. [The role of calcium antagonists on coronary artery spasm and prevention of restenosis after angioplasty]. Kocurek A; Piwowarska W Przegl Lek; 1997; 54(1):37-42. PubMed ID: 9190633 [TBL] [Abstract][Full Text] [Related]
49. The effects of calcium antagonists after PTCA. Hoberg E Eur Heart J; 1995 Aug; 16 Suppl H():9-12. PubMed ID: 8846803 [TBL] [Abstract][Full Text] [Related]
50. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Brogden RN; Benfield P Drugs; 1996 May; 51(5):792-819. PubMed ID: 8861548 [TBL] [Abstract][Full Text] [Related]
51. [Restenosis after PTCA]. Heidland UE; Michel CJ; Heintzen MP; Strauer BE Dtsch Med Wochenschr; 1998 Jul; 123(27):840-6. PubMed ID: 9685844 [No Abstract] [Full Text] [Related]
52. Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study. Herrman JP; Simon R; Umans VA; Peerboom PF; Keane D; Rijnierse JJ; Bach D; Kobi P; Kerry R; Close P Eur Heart J; 1995 Nov; 16 Suppl L():56-62. PubMed ID: 8869020 [TBL] [Abstract][Full Text] [Related]
53. Pharmacologic effects of calcium channel blockers on restenosis. Thaulow E J Cardiovasc Pharmacol; 1999; 33 Suppl 2():S12-6. PubMed ID: 10071258 [TBL] [Abstract][Full Text] [Related]
54. Clinical promise of calcium antagonists in the angioplasty patient. Thaulow E; Jörgensen B Eur Heart J; 1997 May; 18 Suppl B():B21-6. PubMed ID: 9152666 [TBL] [Abstract][Full Text] [Related]
55. Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA. Vahanian A; Lung B Drugs; 1996; 52 Suppl 4():9-15; discussion 15-6. PubMed ID: 8913714 [TBL] [Abstract][Full Text] [Related]
56. Medical approaches to prevention of restenosis after coronary angioplasty. Blackshear JL; O'Callaghan WG; Califf RM J Am Coll Cardiol; 1987 Apr; 9(4):834-48. PubMed ID: 2951423 [TBL] [Abstract][Full Text] [Related]
57. Prevention of restenosis after coronary angioplasty: a pharmacological approach. Meier B Eur Heart J; 1989 Dec; 10 Suppl G():64-8. PubMed ID: 2697565 [TBL] [Abstract][Full Text] [Related]